Progress and Challenge of Artificial Intelligence in Diagnosis and Treatment of Cervical Lesions

doi:10.12114/j.issn.1007-9572.2022.0095

Chinese General Practice ›› 2022, Vol. 25 ›› Issue (18): 2215-2222.DOI: 10.12114/j.issn.1007-9572.2022.0095

• Article·Cervical Cancer Study • Previous Articles Next Articles

Progress and Challenge of Artificial Intelligence in Diagnosis and Treatment of Cervical Lesions

1. Affiliated Tumor Hospital of Xinjiang Medical University/State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Urumqi 830011, China
2. School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China

Received:2022-01-25 Revised:2022-03-01 Published:2022-06-20 Online:2022-04-20
Contact: ·Rezhake REMILA
About author:
WU A Y, REMILA R, QIAO Y L. Progressand challenge of artificial intelligencein diagnosis and treatment of cervical lesions[J]. Chinese General Practice, 2022, 25 (18) : 2215-2222, 2230.

人工智能在宫颈病变诊断及治疗中的应用进展与挑战

1.830011　新疆维吾尔自治区乌鲁木齐市，新疆医科大学附属肿瘤医院　省部共建中亚高发病成因与防治国家重点实验室
2.100730　北京市，中国医学科学院北京协和医学院群医学及公共卫生学院

通讯作者: 热米拉·热扎克
作者简介:
武爱媛，热米拉·热扎克，乔友林.人工智能在宫颈病变诊断及治疗中的应用进展与挑战[J].中国全科医学，2022，25（18）：2215-2222，2230. [www.chinagp.net] 作者贡献：武爱媛进行文章的构思与设计，提出主要分析指标，负责检索文献、撰写论文；热米拉·热扎克进行论文的修订、质量控制及审校；乔友林对文章整体负责，监督管理。
基金资助:
省部共建中亚高发病成因与防治国家重点实验室开放课题资助项目(SKL-HIDCA-2020-GJ2); 新疆医科大学研究生创新创业项目

Abstract

Abstract:

China has the considerable disease burden of cervical cancer, with the mortality and morbidity of cervical cancer showing an increasing and younger trend. Facing to the critical situation of cervical cancer control, it is urgent to explore the new methods that suitable for different resource areas for the early detection and treatment of cervical cancer. Recently, great progress has been made in the field of AI image classification, and scientists have developed many algorithms to identify cervical lesions and conducted corresponding studies on their accuracy. Here, by reviewing the papers published at home and aboard, which studied the applications value of AI in cervical cytology screening, colposcopy examination, diagnosis and treatment of cervical cancer, we summarized and discussed the current progress and challenges for AI's application in the area of cervical cancer control, in order to provide solid evidence for the future use of AI in improving human health.

Key words: Uterine cervical diseases, Artificial intelligence, Cytological techniques, Cervical cytology, Colposcopy, Screening, Diagnosis, differential, Treatment

摘要：

我国宫颈癌的疾病负担较重，其发病率和死亡率呈逐年升高且年轻化趋势，防控形势较为严峻，急需探索适宜我国不同资源地区的、新型的早诊早治手段，以加快我国宫颈癌的防治步伐。近些年人工智能（AI）在图像分类领域取得较大进展，科学家们开发出众多能够识别宫颈病变的算法，并对其准确性进行了相应的研究。本文结合国内外研究成果，就AI在宫颈细胞学筛查、阴道镜、宫颈恶性肿瘤的诊断及治疗预测过程等方面的应用进展进行综述，并探讨AI在宫颈病变诊断及治疗中遇到的挑战，使AI协助医疗工作者更好地为人类健康保驾护航。

关键词: 宫颈疾病, 人工智能, 细胞学技术, 宫颈细胞学, 阴道镜检查, 筛查, 诊断, 鉴别, 治疗

Aiyuan WU,·Rezhake REMILA,Youlin QIAO. Progress and Challenge of Artificial Intelligence in Diagnosis and Treatment of Cervical Lesions[J]. Chinese General Practice, 2022, 25(18): 2215-2222. DOI: 10.12114/j.issn.1007-9572.2022.0095.
武爱媛,热米拉·热扎克,乔友林. 人工智能在宫颈病变诊断及治疗中的应用进展与挑战[J]. 中国全科医学, 2022, 25(18): 2215-2222. DOI: 10.12114/j.issn.1007-9572.2022.0095.

Figures/Tables 3

References 49

[1]	BUCCHI L, BALDACCHINI F, MANCINI S，et al. Estimating the impact of an organised screening programme on cervical cancer incidence：a 26-year study from northern Italy[J]. Int J Cancer，2019，144(5):1017-1026. DOI：10.1002/ijc.31806.
[2]	ZHAO F H, QIAO Y L. Cervical cancer prevention in China：a key to cancer control[J]. Lancet，2019，393(10175):969-970. DOI：10.1016/S0140-6736(18)32849-6.
[3]	BRAY F, FERLAY J, SOERJOMATARAM I，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin，2018，68(6):394-424. DOI：10.3322/caac.21492
[4]	CANFELL K. Towards the global elimination of cervical cancer[J]. Papillomavirus Res，2019，8:100170. DOI：10.1016/j.pvr.2019.100170.
[5]	GULSHAN V, PENG L, CORAM M，et al. Development and validation of a deep learning algorithm for detection of diabetic retinopathy in retinal fundus photographs[J]. JAMA，2016，316(22):2402-2410. DOI：10.1001/jama.2016.17216.
[6]	ESTEVA A, KUPREL B, NOVOA R A，et al. Dermatologist-level classification of skin cancer with deep neural networks[J]. Nature，2017，542(7639):115-118. DOI：10.1038/nature21056.
[7]	CHILAMKURTHY S, GHOSH R, TANAMALA S，et al. Deep learning algorithms for detection of critical findings in head CT scans：a retrospective study[J]. Lancet，2018，392(10162):2388-2396. DOI：10.1016/S0140-6736(18)31645-3.
[8]	TSIKOURAS P, ZERVOUDIS S, MANAV B，et al. Cervical cancer：screening，diagnosis and staging[J]. J BUON，2016，21(2):320-325.
[9]	WANG B H, HE M F, CHAO A，et al. Cervical cancer screening among adult women in China，2010[J]. Oncologist，2015，20(6):627-634. DOI：10.1634/theoncologist.2014-0303.
[10]	OGILVIE G S, KRAJDEN M, VAN NIEKERK D，et al. HPV for cervical cancer screening （HPV FOCAL）：complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer[J]. Int J Cancer，2017，140(2):440-448. DOI：10.1002/ijc.30454.
[11]	KOLIOPOULOS G, NYAGA V N, SANTESSO N，et al. Cytology versus HPV testing for cervical cancer screening in the general population[J]. Cochrane Database Syst Rev，2017，8(8):Cd008587. DOI：10.1002/14651858.CD008587.
[12]	WILLIAM W, WARE A, BASAZA-EJIRI A H，et al. A review of image analysis and machine learning techniques for automated cervical cancer screening from pap-smear images[J]. Comput Methods Programs Biomed，2018，164:15-22. DOI：10.1016/j.cmpb.2018.05.034.
[13]	BAO H L, BI H, ZHANG X S，et al. Artificial intelligence-assisted cytology for detection of cervical intraepithelial neoplasia or invasive cancer：a multicenter，clinical-based，observational study[J]. Gynecol Oncol，2020，159(1):171-178. DOI：10.1016/j.ygyno.2020.07.099.
[14]	BAO H L, SUN X R, ZHANG Y，et al. The artificial intelligence-assisted cytology diagnostic system in large-scale cervical cancer screening：a population-based cohort study of 0.7 million women[J]. Cancer Med，2020，9(18):6896-6906. DOI：10.1002/cam4.3296.
[15]	TANG H P, CAI D, KONG Y Q，et al. Cervical cytology screening facilitated by an artificial intelligence microscope：a preliminary study[J]. Cancer Cytopathol，2021，129(9):693-700. DOI：10.1002/cncy.22425.
[16]	WENTZENSEN N, LAHRMANN B, CLARKE M A，et al. Accuracy and efficiency of deep-learning-based automation of dual stain cytology in cervical cancer screening[J]. J Natl Cancer Inst，2021，113(1):72-79. DOI：10.1093/jnci/djaa066.
[17]	ZHU X H, LI X M, ONG K，et al. Hybrid AI-assistive diagnostic model permits rapid TBS classification of cervical liquid-based thin-layer cell smears[J]. Nat Commun，2021，12(1):3541. DOI：10.1038/s41467-021-23913-3.
[18]	LI X, XU Z H, SHEN X，et al. Detection of cervical cancer cells in whole slide images using deformable and global context aware faster RCNN-FPN[J]. Curr Oncol，2021，28(5):3585-3601. DOI：10.3390/curroncol28050307.
[19]	SENKOMAGO V, ROYALTY J, MILLER J W，et al. Cervical cancer screening in the National Breast and Cervical Cancer Early Detection Program （NBCCEDP） in four US-Affiliated Pacific Islands between 2007 and 2015[J]. Cancer Epidemiol，2017，50:260-267. DOI：10.1016/j.canep.2017.04.011.
[20]	DEVI M A, RAVI S, VAISHNAVI J，et al. Classification of cervical cancer using artificial neural networks[J]. Procedia Comput Sci，2016，89:465-472. DOI：10.1016/j.procs.2016.06.105.
[21]	THRALL M J. Automated screening of Papanicolaou tests：a review of the literature[J]. Diagn Cytopathol，2019，47(1):20-27. DOI：10.1002/dc.23931.
[22]	RENSHAW A A, HOLLADAY E B, GEILS K B. Results of multiple-slide，blinded review of Papanicolaou slides in the context of litigation. Determining what can be detected regularly and reliably[J]. Cancer，2005，105(5):263-269. DOI：10.1002/cncr.21319.
[23]	DOORNEWAARD H, VAN DEN TWEEL J G, JONES H W, 3rd. Applications of automation in cervical cancer screening[J]. J Low Genit Tract Dis，1998，2(1):19-24. DOI：10.1097/00128360-199801000-00005.
[24]	中国病理医师协会数字病理与人工智能病理学组，中华医学会病理学分会数字病理与人工智能工作委员会，中华医学会病理学分会细胞病理学组.宫颈液基细胞学的数字病理图像采集与图像质量控制中国专家共识[J]. 中华病理学杂志，2021，50(4):4. DOI：10.3760/cma.j.cn112151-20210111-00028.
[25]	OGILVIE G, NAKISIGE C, HUH W K，et al. Optimizing secondary prevention of cervical cancer：recent advances and future challenges[J]. Int J Gynaecol Obstet，2017，138(Suppl 1):15-19. DOI：10.1002/ijgo.12187.
[26]	XUE P, NG M T A, QIAO Y L. The challenges of colposcopy for cervical cancer screening in LMICs and solutions by artificial intelligence[J]. BMC Med，2020，18:169. DOI：10.1186/s12916-020-01613-x.
[27]	赵昀，魏丽惠. 我国阴道镜技术培训何去何从[J]. 中国妇产科临床杂志，2019，20(1):1-2. DOI：10.13390/j.issn.1672-1861.2019.01.001.
[28]	赵宇倩.适合中国不同资源地区的宫颈癌筛查技术及阴道镜检查中组织学活检的探讨[D]. 北京：北京协和医学院，2016.
[29]	王娜，王悦.人工智能在子宫颈癌筛查中的应用[J]. 中华妇产科杂志，2020，55(11):4. DOI：10.3760/cma.j.cn112141-20200405-00299.
[30]	SATO M, HORIE K, HARA A，et al. Application of deep learning to the classification of images from colposcopy[J]. Oncol Lett，2018:15(3):3518-3523. DOI：10.3892/ol.2018.7762.
[31]	HU L, BELL D, ANTANI S，et al. An observational study of deep learning and automated evaluation of cervical images for cancer screening[J]. J Natl Cancer Inst，2019，111(9):923-932. DOI：10.1093/jnci/djy225.
[32]	MIYAGI Y, TAKEHARA K, MIYAKE T. Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images[J]. Mol Clin Oncol，2019，11(6):583-589. DOI：10.3892/mco.2019.1932.
[33]	MIYAGI Y, TAKEHARA K, NAGAYASU Y，et al. Application of deep learning to the classification of uterine cervical squamous epithelial lesion from colposcopy images combined with HPV types[J]. Oncol Lett，2020，19(2):1602-1610. DOI：10.3892/ol.2019.11214.
[34]	CHO B J, CHOI Y J, LEE M J，et al. Classification of cervical neoplasms on colposcopic photography using deep learning[J]. Sci Rep，2020，10(1):13652. DOI：10.1038/s41598-020-70490-4.
[35]	薛鹏，乔友林，江宇. 人工智能在医学内窥镜诊断中的应用[J]. 中华肿瘤杂志，2018，40(12):890-893. DOI：10.3760/cma.j.issn.0253-3766.2018.12.003.
[36]	XUE P, TANG C, LI Q，et al. Development and validation of an artificial intelligence system for grading colposcopic impressions and guiding biopsies[J]. BMC Med，2020，18(1):406. DOI：10.1186/s12916-020-01860-y.
[37]	LIU L, WANG Y, LIU X L，et al. Computer-aided diagnostic system based on deep learning for classifying colposcopy images[J]. Ann Transl Med，2021，9(13):1045. DOI：10.21037/atm-21-885.
[38]	薛鹏，唐朝，乔友林，等. 人工智能电子阴道镜辅助诊断系统对宫颈癌筛查的现实挑战和未来机遇[J]. 中国肿瘤，2019，28(7):483-486. DOI：10.11735/j.issn.1004-0242.2019.07.A001.
[39]	SOUMYA K, SNEHA K, ARUNVINODH C. Cervical cancer detection and classification using texture analysis[J]. Biomed Pharmacol J，2016，9(2):663-671. DOI：10.13005/bpj/988.
[40]	NITHYA B, ILANGO V. Evaluation of machine learning based optimized feature selection approaches and classification methods for cervical cancer prediction[J]. SN Appl Sci，2019，1(6):1-16. DOI：10.1007/s42452-019-0645-7.
[41]	WANG T, GAO T T, YANG J B，et al. Preoperative prediction of pelvic lymph nodes metastasis in early-stage cervical cancer using radiomics nomogram developed based on T2-weighted MRI and diffusion-weighted imaging[J]. Eur J Radiol，2019，114:128-135. DOI：10.1016/j.ejrad.2019.01.003.
[42]	MATSUO K, PURUSHOTHAM S, MOEINI A，et al. A pilot study in using deep learning to predict limited life expectancy in women with recurrent cervical cancer[J]. Am J Obstet Gynecol，2017，217(6):703-705. DOI：10.1016/j.ajog.2017.08.012.
[43]	MATSUO K, PURUSHOTHAM S, JIANG B，et al. Survival outcome prediction in cervical cancer：Cox models vs deep-learning model[J]. Am J Obstet Gynecol，2019，220(4):381.e1-381.e4. DOI：10.1016/j.ajog.2018.12.030.
[44]	AKAZAWA M, HASHIMOTO K. Artificial intelligence in gynecologic cancers：current status and future challenges——a systematic review[J]. Artif Intell Med，2021，120:102164. DOI：10.1016/j.artmed.2021.102164.
[45]	SHEN W C, CHEN S W, WU K C，et al. Prediction of local relapse and distant metastasis in patients with definitive chemoradiotherapy-treated cervical cancer by deep learning from[18F]-fluorodeoxyglucose positron emission tomography/computed tomography[J]. SSRN Journal，2019，29(12):6741-6749. DOI：10.2139/ssrn.3292576.
[46]	PERGIALIOTIS V, POULIAKIS A, PARTHENIS C，et al. The utility of artificial neural networks and classification and regression trees for the prediction of endometrial cancer in postmenopausal women[J]. Public Health，2018，164:1-6. DOI：10.1016/j.puhe.2018.07.012.
[47]	ARAMENDÍA-VIDAURRETA V, CABEZA R, VILLANUEVA A，et al. Ultrasound image discrimination between benign and malignant adnexal masses based on a neural network approach[J]. Ultrasound Med Biol，2016，42(3):742-752. DOI：10.1016/j.ultrasmedbio.2015.11.014.
[48]	ACHARYA U R, SREE S V, KULSHRESHTHA S，et al. GyneScan：an improved online paradigm for screening of ovarian cancer via tissue characterization[J]. Technol Cancer Res Treat，2014，13(6):529-539. DOI：10.7785/tcrtexpress.2013.600273.
[49]	ZHANG L, HUANG J, LIU L. Improved deep learning network based in combination with cost-sensitive learning for early detection of ovarian cancer in color ultrasound detecting system[J]. J Med Syst，2019，43(8):251. DOI：10.1007/s10916-019-1356-8.

作者	时间（年）	地点	例数	图像数据集	种类	细胞	训练软件	优势
BAO等^[13]	2020	多中心观察研究	2 145	8 329张数字细胞图像	TBS制片	188 542张图块（121 940张异常/66 602张正常	ResNet	初筛/分诊中在诊断CIN 2+级的准确性较优
BAO等^[14]	2020	多中心观察研究	703 103	8 329份细胞学样本	TBS制片	103 793份图像（32 859份异常/70 934份正常	深度学习算法	识别大部分正常细胞
TANG等^[15]	2021	深圳市妇幼保健院	10 601	2 167份细胞学样本	TBS制片	42 078异常细胞	RetinaNet	实时辅助诊断
WENTZENSEN等^[16]	2020	俄克拉荷马大学健康科学中心	4 253	431份样本训练/3 504份样本验证	P16/Ki-67双重染色涂片	431份图像〔8 956 DS（+）/10 692 DS（-）图块训练〕	CNN	具有自动化、客观性及较强的稳定性
ZHU等^[17]	2021	中国5个医疗中心	未知	81 727份样本训练/34，403份样本验证	TBS制片	未知	AIATBS	适用于不同设备，阅片速度<180 s/玻片
LI等^[18]	2021	宫颈细胞学图像数据集	未知	500张阳性/300张阴性	巴氏涂片	未知	Faster R-CNN-FPN模型	自动识别检测整张巴氏图像

作者	时间（年）	地点	例数	图像数据集	种类	细胞	训练软件	优势
BAO等^[13]	2020	多中心观察研究	2 145	8 329张数字细胞图像	TBS制片	188 542张图块（121 940张异常/66 602张正常	ResNet	初筛/分诊中在诊断CIN 2+级的准确性较优
BAO等^[14]	2020	多中心观察研究	703 103	8 329份细胞学样本	TBS制片	103 793份图像（32 859份异常/70 934份正常	深度学习算法	识别大部分正常细胞
TANG等^[15]	2021	深圳市妇幼保健院	10 601	2 167份细胞学样本	TBS制片	42 078异常细胞	RetinaNet	实时辅助诊断
WENTZENSEN等^[16]	2020	俄克拉荷马大学健康科学中心	4 253	431份样本训练/3 504份样本验证	P16/Ki-67双重染色涂片	431份图像〔8 956 DS（+）/10 692 DS（-）图块训练〕	CNN	具有自动化、客观性及较强的稳定性
ZHU等^[17]	2021	中国5个医疗中心	未知	81 727份样本训练/34，403份样本验证	TBS制片	未知	AIATBS	适用于不同设备，阅片速度<180 s/玻片
LI等^[18]	2021	宫颈细胞学图像数据集	未知	500张阳性/300张阴性	巴氏涂片	未知	Faster R-CNN-FPN模型	自动识别检测整张巴氏图像

作者	时间（年）	地点	例数	图像数据集	种类	正常	LSIL	HSIL	肿瘤	训练软件	优势	备注
SATO等^[29]	2018	日本埼玉县癌症中心	158	485	阴道镜图像	0	142^a		343	Keras神经网络/Tensor Flow库	阴道镜图像病变级别分类	单纯验证
HU等^[30]	2019	美国哥斯达黎加省	9 406	9 406	阴道镜图像	279^b		9 127^c		Faster R-CNN	支持数字阴道镜图像的自动视觉评估	训练集：744张图像，测试集：324张图像，筛查集：8 259张图像^d
MIYAGI等^[31]	2019	国立医院组织妇产科	330	未知	阴道镜图像	0	97	213	30	CNN	HSIL/LSIL分类	—
MIYAGI等^[32]	2020	柴达木医科大学国际医学中心	253	未知	阴道镜图像	0	210	43	0	CNN+HPV分型	AI与阴道镜及HPV分型结合用于HSIL/LSIL分类	—
CHO等^[33]	2020	韩国多中心大学附属医院	791	791	阴道镜图像	126	100	522	43	Inception-Resnet-v2模型/Resnet-152模型，Keras检测病变区域	检测HSIL+及宫颈病变区域预测分析	—
XUE等^[35]	2020	中国6家医院	19 435	101 267	阴道镜图像	6 013	5 932	6 389	1 101	CAIADS训练+优化+验证为7∶1∶2	HSIL+/LSIL+分级及宫颈病变区域预测分析	训练集：13 604例患者86 037张图像；优化：1 944例患者9 751张图像；验证：3 887例患者23 479张图像
LIU等^[36]	2021	山东齐鲁医院	7 530	15 276	阴道镜图像	3 966	1 411	1 966	157	ResNet（训练+验证+测试：7∶1∶2）	AI与宫颈疾病临床特征结合用于宫颈病变分类	训练集：5 271例患者10 650张图像，验证集：753名例患者1 531张，测试集：1 506例患者3 095张图像

作者	时间（年）	地点	例数	图像数据集	种类	正常	LSIL	HSIL	肿瘤	训练软件	优势	备注
SATO等^[29]	2018	日本埼玉县癌症中心	158	485	阴道镜图像	0	142^a		343	Keras神经网络/Tensor Flow库	阴道镜图像病变级别分类	单纯验证
HU等^[30]	2019	美国哥斯达黎加省	9 406	9 406	阴道镜图像	279^b		9 127^c		Faster R-CNN	支持数字阴道镜图像的自动视觉评估	训练集：744张图像，测试集：324张图像，筛查集：8 259张图像^d
MIYAGI等^[31]	2019	国立医院组织妇产科	330	未知	阴道镜图像	0	97	213	30	CNN	HSIL/LSIL分类	—
MIYAGI等^[32]	2020	柴达木医科大学国际医学中心	253	未知	阴道镜图像	0	210	43	0	CNN+HPV分型	AI与阴道镜及HPV分型结合用于HSIL/LSIL分类	—
CHO等^[33]	2020	韩国多中心大学附属医院	791	791	阴道镜图像	126	100	522	43	Inception-Resnet-v2模型/Resnet-152模型，Keras检测病变区域	检测HSIL+及宫颈病变区域预测分析	—
XUE等^[35]	2020	中国6家医院	19 435	101 267	阴道镜图像	6 013	5 932	6 389	1 101	CAIADS训练+优化+验证为7∶1∶2	HSIL+/LSIL+分级及宫颈病变区域预测分析	训练集：13 604例患者86 037张图像；优化：1 944例患者9 751张图像；验证：3 887例患者23 479张图像
LIU等^[36]	2021	山东齐鲁医院	7 530	15 276	阴道镜图像	3 966	1 411	1 966	157	ResNet（训练+验证+测试：7∶1∶2）	AI与宫颈疾病临床特征结合用于宫颈病变分类	训练集：5 271例患者10 650张图像，验证集：753名例患者1 531张，测试集：1 506例患者3 095张图像

数量	作者	时间（年）	数据集	使用数据	AI模型	应用
3项^a	URUSHIBARA	2020	418	MRI	CNN	诊断宫颈癌分期
	WANG	2020	95	MRI	SVM	诊断宫颈癌分期
	SOUMYA	2020	24	MRI	SVM	诊断宫颈癌分期
15项^b	CHEN	2020	127	CT	SVM	淋巴结转移
	TIAN	2020	277	CT	RF	新辅助化疗的应答
	YAN	2020	190	MRI	CNN	淋巴结转移
	DONG	2020	226	MRI	CNN	淋巴结转移
	WU	2020	894	MRI	CNN	淋巴结转移
	WANG	2020	137	MRI	SVM	子宫旁组织的浸润
	HUA	2020	111	MRI	CNN	子宫旁组织的浸润
	WANG	2019	96	MRI	SVM	淋巴结转移
	WU	2019	189	MRI	SVM/DT	淋巴结转移
	TAKADA	2020	87	MRI	RF	同步放化疗后复发
	PARK	2020	93	MRI	RF	同步放化疗后复发（中位随访38个月）
	MENG J	2018	34	MRI	SVM	同步放化疗后复发（中位随访31个月）
	TORHEIM T	2014	81	MRI	SVM	同步放化疗后复发（中位随访56个月）
	SHEN	2019	142	PET-CT	CNN	同步放化疗后复发（中位随访40个月）
	ROMAN JG	2016	53	PET-CT	RF	同步放化疗后复发（中位随访42个月）
10项^c	WEEGAR	2020	175 533	临床指标	SVM/NB/RF	诊断
	ASADI	2020	145	临床指标	SVM/ANN	诊断
	IJAZ	2020	858	临床指标	SVM/RF/KNN/ANN/NB	诊断
	ALSMARITY	2020	858	临床指标	DT/RF	诊断
	NITHYA	2019	858	临床指标	SVM/RF/KNN/RPART/C5.0	诊断
	SUMAN	2019	858	临床指标	ANN/SVM/RF/DT/Ada/Bayes	诊断
	GEETHA	2019	858	临床指标	RF	诊断
	FERNANDES	2018	858	临床指标	ANN/SVM/KNN/DT	诊断
	ABDOH	2018	858	临床指标	RF	诊断
	WU	2017	858	临床指标	SVM	诊断
6项^d	XIE	2020	647	临床指标	SVM	无进展生存期和总生存期(时间长短)
	MATSUO	2019	768	临床指标	ANN	无进展生存期和总生存期(时间长短)
	MATSUO	2017	157	临床指标	ANN	复发后3个月和6个月生存率
	OBRZUT	2017	102	临床指标	ANN/SVM/GEP/Κ-Means method	5年总生存率
	PAPADIA	2015	101	临床指标	ANN	新辅助化疗和根治性手术后需要辅助放疗
	TSENG	2013	168	临床指标	SVM/C5.0/ELM	复发(随访时间不明确)

Progress and Challenge of Artificial Intelligence in Diagnosis and Treatment of Cervical Lesions

人工智能在宫颈病变诊断及治疗中的应用进展与挑战

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 49

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	YAO Yuzhong, MA Xiaojun, SONG Huan, ZHONG Yu. The Management Effect of Diabetes "1358 model" on Community Diabetes Patients Based on "Precision Management Combining General Care and Specialty Care" [J]. Chinese General Practice, 2023, 26(34): 4308-4314.
[2]	QIN Fengyin, ZHANG Qishan, LAI Jinjia, HUANG Yimin, HAN Guoyin, SUN Xinglan, WANG Fen, TAN Yibing. Current Status and Influencing Factors of the Intention to Screen for High-risk Stroke among Community Residents in Guangdong [J]. Chinese General Practice, 2023, 26(34): 4283-4289.
[3]	WANG Zhe, DONG Zhihao, ZHENG Hao, KONG Wencheng, ZHANG Yukuan, ZHANG Qiuyue, HAN Jing. Construction of Optimized Treatment Plan of Acupuncture for Migraine Based on Entropy Weight-TOPSIS Method [J]. Chinese General Practice, 2023, 26(34): 4336-4342.
[4]	LI Dianjiang, PAN Enchun, SUN Zhongming, WEN Jinbo, WANG Miaomiao, WU Ming, SHEN Chong. The Current Status and Influencing Factors of Clinical Inertia in Type 2 Diabetes Patients in Community [J]. Chinese General Practice, 2023, 26(34): 4296-4301.
[5]	LIN Kai, YAO Mi, CHEN Zhang, JI Xinxin, LIN Runqi, CHEN Yongsong, Sim MOIRA. Conceptual Framework and Responding Approach of Treatment Burden of Type 2 Diabetes: a Video Recording-based Analysis [J]. Chinese General Practice, 2023, 26(34): 4302-4307.
[6]	WANG Jie, LI Shiming, WEI Shifei, WANG Ningli. Importance of the Role of Primary Care in Myopia Prevention and Control Behavioral Intervention among Children [J]. Chinese General Practice, 2023, 26(33): 4213-4217.
[7]	GAO Jing, ZHOU Shangcheng, GAO Sande, ZOU Guanyang, CHEN Yingyao. Health-related Quality of Life and Its Influencing Factors in Patients with Prevention of Disease in Traditionnal Chinese Medicine based on EQ-5D-5L Scale [J]. Chinese General Practice, 2023, 26(32): 4043-4050.
[8]	LU Guangqi, ZHUANG Minghui, ZHU Liguo, GAO Jinghua, WEI Xu, LI Luguang, YU Jie. Interpretation of Best Practices for Minimally Invasive Lumbar Spinal Stenosis Treatment 2.0 (MIST) : Consensus Guidance from the American Society of Pain and Neuroscience (ASPN) in 2022 [J]. Chinese General Practice, 2023, 26(32): 3995-4000.
[9]	LI Qian, ZHANG Yunshu, YAN Baoping, WANG Jian, MA Yanjuan, WANG Yuan, QIN Yingjie, NA Long, REN Zhiyong, SUN Junwei, DENG Huaili, MA Hongjun, QU Xuehui, ZHOU Nan, SI Tianmei. Efficacy and Safety of Risperidone Microspheres for Injection (Ⅱ) in the Treatment of Patients with Acute Schizophrenia [J]. Chinese General Practice, 2023, 26(32): 4007-4012.
[10]	LOU Zheng, LIU Ying, REN Jingjing. Visits for Medically Unspecified Disease in General Internal Medicine Clinics of County General Hospitals [J]. Chinese General Practice, 2023, 26(31): 3945-3950.
[11]	ZHU Lin, GUO Yankui, GAO Chen, CHEN Xuezhi, WANG Fashuai. Efficacy of Western Medicine, Chinese Patent Medicine and Their Combination on Post-stroke Insomnia: a Network Meta-analysis [J]. Chinese General Practice, 2023, 26(30): 3823-3832.
[12]	LIU Ruifang, XU Fangxing, LIU Tongku, ZHOU Yujie, WU Xiaofan. Evaluation of the Efficacy and Safety of "Crowbar Effect" Technique to Facilitate Balloon Crossing Resistant Chronic Total Occlusions Lesions [J]. Chinese General Practice, 2023, 26(29): 3683-3688.
[13]	WANG Yudong, MA Xiaojing, WANG Fang. Influence Mechanism of Capitation for Outpatient Services in Basic Medical Insurance on Medical Expenses Based on the Concept of System Dynamics: a Case Study of Outpatient Payment Mode Reform in Shengzhou, Zhejiang Province [J]. Chinese General Practice, 2023, 26(28): 3496-3501.
[14]	CHENG Xiaoran, ZHANG Xiaotian, LI Mingyue, CHENG Haozhe, TANG Haoqing, ZHENG Huixian, ZHANG Baisong, LIU Xiaoyun. Impact of Chronic Diseases Follow-up on Health Behaviors and Blood Pressure/Glucose Control of Patients with Hypertension and Diabetes in the Context of Treatment-prevention Integration [J]. Chinese General Practice, 2023, 26(28): 3482-3488.
[15]	CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470.